Clinical trials: Small Cell Lung Carcinoma Extensive Disease
Small Cell Lung Cancer
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).
- Trial name
- NCT06581380
- Testing
- JK-1201I, Topotecan
- Volunteers
- 394 people
- Sponsor
- JenKem Technology Co., Ltd.
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation [TBI]) and higher dose radiation to known areas of cancer (hypofractionated radiation…
- Trial name
- TESSERACT (NCT06110572)
- Testing
- Carboplatin, Atezolizumab, Etoposide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Small Cell Lung Cancer
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab
- Trial name
- NCT05882630
- Testing
- Surufatinib,Serplulimab,Etoposide,Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Lung Cancer, NSCLC Stage IV
Lung Cancer Registry
Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer.
- Conditions
- Lung Cancer, NSCLC Stage IV, NSCLC, Stage III, SCLC, Extensive Stage
- Trial name
- NCT04654364
- Where
- 3 sites in Austria
- Volunteers
- 290 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Non-small Cell Lung Cancer, Extensive Stage Unresectable
Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer
Primary Objective: To determine the maximum tolerated dose of docetaxel when given with Irinotecan and Carboplatin for the treatment of inoperable lung cancer.
- Trial name
- NCT00264134
- Testing
- Docetaxel, Irinotecan, Carboplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kentuckiana Cancer Institute
Lung Cancer
Studying Patterns, Causes, and Control of Disease in Patients With Lung Cancer in the North Trent (England) Region
RATIONALE: Gathering information about genetic and environmental factors from patients with lung cancer and their partners and first-degree relatives may help doctors learn more about the disease.
- Trial name
- NCT00693836
- Testing
- genetic linkage analysis, loss of heterozygosity analysis, mutation analysis
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cancer Research Centre at Weston Park Hospital
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
- Trial name
- NCT07744256
- Testing
- EB-DART-NK01, Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Extensive-stage Small Cell Lung Cancer
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.
- Trial name
- NCT04562337
- Testing
- SHR1316, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer, Chronic Myeloproliferative Disorders
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00036790
- Testing
- doxorubicin hydrochloride, motexafin gadolinium
- Where
- 2 sites in United States
- Sponsor
- University of Wisconsin, Madison
Dysphagia, Lung Cancer
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy and radiation therapy. It is not yet known whether Manuka honey is more effective than standard care in preventing pain.
- Conditions
- Dysphagia, Lung Cancer, Pain, Esophagitis
- Trial name
- NCT01262560
- Testing
- Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care
- Where
- 59 sites in United States
- Volunteers
- 163 people
- Sponsor
- Radiation Therapy Oncology Group
Solid Tumor, Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)
This study using pembrolizumab (MK-3475) will be done in 5 parts. In Part A, successive participant cohorts with advanced solid tumors will receive pembrolizumab to assess the safety and tolerability of monotherapy.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01840579
- Testing
- Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 200 mg
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive Stage Small Cell Lung Cancer
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
- Trial name
- NCT05361395
- Testing
- Tarlatamab, Carboplatin, Etoposide
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 184 people
- Sponsor
- Amgen
Small Cell Lung Cancer
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and…
- Trial name
- ALISCA-Lung1 (NCT06095505)
- Testing
- Alisertib
- Where
- 30 sites in United States
- Volunteers
- 120 people
- Sponsor
- Puma Biotechnology, Inc.
Small Cell Lung Cancer Extensive Stage
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy.
- Trial name
- TAXIO (NCT05856695)
- Testing
- Carboplatin + Paclitaxel + Durvalumab
- Where
- 31 sites in France
- Volunteers
- 67 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer, Small Cell
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
- Trial name
- NCT00316186
- Testing
- topotecan, carboplatin
- Where
- 13 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
In this study, all patients must have already completed first-line chemotherapy to treat extensive-stage disease small cell lung cancer.
- Trial name
- CheckMate 451 (NCT02538666)
- Testing
- Nivolumab, Ipilimumab
- Where
- 197 sites in United States, Argentina and 30 more
- Volunteers
- 907 people
- Sponsor
- Bristol-Myers Squibb
Small Cell Lung Cancer
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
To evaluate the efficacy and safety of maintenance therapy with Adebrelimab plus Apatinib for extensive stage small cell lung cancer after first-line induction of Adebrelimab plus chemotherapy.
- Trial name
- NCT06480864
- Testing
- Adebrelimab Injection, Apatinib Mesylate Tablets, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 38 people
- Sponsor
- Yunpeng Liu
Small Cell Lung Carcinoma
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer…
- Trial name
- NCT03963414
- Testing
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
Small Cell Lung Cancer
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed.
- Trial name
- NCT00613626
- Testing
- Cisplatin, Etoposide, ZD6474
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Hoosier Cancer Research Network
Small Cell Lung Cancer Extensive Stage
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
This is a multicenter, open-label, non-randomized, single arm, 2 parts, phase II clinical trial evaluating the efficacy and safety of pembrolizumab and lenvatinib plus standard of care chemotherapy (with carboplatin and etoposide…
- Trial name
- PEERS (NCT05384015)
- Testing
- Lenvatinib, Pembrolizumab, Etoposide
- Where
- 18 sites in Spain
- Volunteers
- 46 people
- Sponsor
- Fundación GECP